论文部分内容阅读
目的:许多基因治疗方案可以诱导产生抗肿瘤免疫反应,但是ex vivo的操作方式限制了其应用.本研究采用瘤体内直接注射MHC Ⅱ类基因的方法来诱导抗肿瘤免疫反应.方法:针对具有弱免疫原性的小鼠肥大细胞瘤P815和非免疫原性的小鼠黑色素瘤B16,在瘤体的原位注射MHC Ⅱ类基因,观察肿瘤的生长情况.结果:直接注射MHC Ⅱ类基因,使P815肿瘤的致瘤性明显下降,并且对第二次接种P815细胞具有抵抗能力;虽然对B16而言,仅注射MHC Ⅱ类基因无治疗效果,但与B7基因共同注射,却能够显著地抑制B16肿瘤的生长.结论:瘤体内直接注射MHC Ⅱ类基因可以用来进行肿瘤治疗.
OBJECTIVE: Many gene therapy regimens induce anti-tumor immune responses, but ex vivo methods have limited their utility.In this study, direct injection of MHC class II genes into tumors to induce anti-tumor immune responses.Methods: Immunogenicity of mastocytoma P815 and non-immunogenic mouse melanoma B16 were used to in situ in situ injection of MHC class II gene and the growth of tumor was observed.Results: Direct injection of MHC class II gene The tumorigenicity of P815 tumor was significantly decreased and it was resistant to the second inoculation of P815 cells. Although only injection of MHC class II gene for B16 had no therapeutic effect, co-injection of B7 gene could significantly inhibit B16 Tumor growth.Conclusion: Direct injection of MHC class II gene in tumor can be used for tumor therapy.